Compare RZLT & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RZLT | YDES |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | Taiwan |
| Employees | 58 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.0M | 543.0M |
| IPO Year | 2011 | 2024 |
| Metric | RZLT | YDES |
|---|---|---|
| Price | $4.85 | $6.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $9.80 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 579.3K |
| Earning Date | 11-05-2026 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,481.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $1.70 |
| 52 Week High | $11.46 | $22.00 |
| Indicator | RZLT | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 60.96 |
| Support Level | $4.36 | $2.33 |
| Resistance Level | $5.43 | $8.89 |
| Average True Range (ATR) | 0.31 | 1.28 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 93.48 | 72.88 |
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.